These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 15032664)
1. The role of emerging genomics and proteomics technologies in cancer drug target discovery. Onyango P Curr Cancer Drug Targets; 2004 Mar; 4(2):111-24. PubMed ID: 15032664 [TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
3. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Workman P Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933 [TBL] [Abstract][Full Text] [Related]
4. Anticancer drug discovery using chemical genomics. Sehgal A Curr Med Chem; 2003 May; 10(9):749-55. PubMed ID: 12678778 [TBL] [Abstract][Full Text] [Related]
5. Role of genomics in identifying new targets for cancer therapy. Anzick SL; Trent JM Oncology (Williston Park); 2002 May; 16(5 Suppl 4):7-13. PubMed ID: 12102580 [TBL] [Abstract][Full Text] [Related]
6. Chemical genomics and emerging DNA technologies in the identification of drug mechanisms and drug targets. Olsen LC; Færgeman NJ Curr Top Med Chem; 2012; 12(12):1331-45. PubMed ID: 22690680 [TBL] [Abstract][Full Text] [Related]
7. Bioinformatics Approaches for Anti-cancer Drug Discovery. Li K; Du Y; Li L; Wei DQ Curr Drug Targets; 2020; 21(1):3-17. PubMed ID: 31549592 [TBL] [Abstract][Full Text] [Related]
8. The impact of genomics on therapeutic drug development. Kennedy GC EXS; 2000; 89():1-10. PubMed ID: 10997279 [TBL] [Abstract][Full Text] [Related]
9. Introduction: Cancer Gene Networks. Clarke R Methods Mol Biol; 2017; 1513():1-9. PubMed ID: 27807826 [TBL] [Abstract][Full Text] [Related]
10. New cancer biomarkers deriving from NCI early detection research. Verma M; Srivastava S Recent Results Cancer Res; 2003; 163():72-84; discussion 264-6. PubMed ID: 12903844 [TBL] [Abstract][Full Text] [Related]
11. Expression genomics and drug development: towards predictive pharmacology. Liu ET Brief Funct Genomic Proteomic; 2005 Feb; 3(4):303-21. PubMed ID: 15814022 [TBL] [Abstract][Full Text] [Related]
12. What does systems biology mean for drug development? Schrattenholz A; Soskić V Curr Med Chem; 2008; 15(15):1520-8. PubMed ID: 18537627 [TBL] [Abstract][Full Text] [Related]
13. [Methods of experimental validation of potential target proteins for creation of new drugs]. Ivanov AS; Veselovskiĭ AV; Archakov AI Biomed Khim; 2005; 51(1):2-18. PubMed ID: 15850214 [TBL] [Abstract][Full Text] [Related]
14. SNP technologies for drug discovery: a current review. Voisey J; Morris CP Curr Drug Discov Technol; 2008 Sep; 5(3):230-5. PubMed ID: 18690891 [TBL] [Abstract][Full Text] [Related]
15. Alternative strategies in drug development: clinical pharmacological aspects. Kuhlmann J Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949 [TBL] [Abstract][Full Text] [Related]
16. The promise of structural genomics in the discovery of new antimicrobial agents. Buchanan SG; Sauder JM; Harris T Curr Pharm Des; 2002; 8(13):1173-88. PubMed ID: 12052226 [TBL] [Abstract][Full Text] [Related]
17. TARGETgene: a tool for identification of potential therapeutic targets in cancer. Wu CC; D'Argenio D; Asgharzadeh S; Triche T PLoS One; 2012; 7(8):e43305. PubMed ID: 22952662 [TBL] [Abstract][Full Text] [Related]
18. Towards high-throughput characterization of small molecule mechanisms of action. Luesch H Mol Biosyst; 2006 Dec; 2(12):609-20. PubMed ID: 17216042 [TBL] [Abstract][Full Text] [Related]
19. Application of proteomic technologies in the drug development process. Walgren JL; Thompson DC Toxicol Lett; 2004 Apr; 149(1-3):377-85. PubMed ID: 15093284 [TBL] [Abstract][Full Text] [Related]
20. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS. Verkhivker GM Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]